Belantamab  (Synonyms: 贝兰妥单抗; GSK2857914)

Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

TNFRSF17/BCMA/CD269

608  [NCBI]

Q02223

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.06 kDa

2061894-48-0

液体

Colorless to light yellow

贝兰妥单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized BCMA/TNFRSF17 Protein, Human can bind Belantamab. The EC₅₀ for this effect is 8.0 ng/mL.
• 
  Loaded Belantamab on AHC2 biosensor, can bind BCMA/TNFRSF17 Protein, Human (HEK293, His, HY-P72847) with an affinity constant of 3.934E-10 M as determined in BLI assay.

• [1]. Ivo Demel, et al. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021. Br J Haematol. 2021 May;193 (4) :705-722.  [Content Brief]

  [2]. Montes de Oca R, et al. Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo. Mol Cancer Ther. 2021 Oct;20 (10) :1941-1955.  [Content Brief]